Skip to main content
Premium Trial:

Request an Annual Quote

IMC Selects Expression Analysis for Microarray Processing Services

NEW YORK, June 8 (GenomeWeb News) - IMC selected Expression Analysis for microarray processing services to support its clinical trial on drug addiction, Expression Analysis said today.

The Durham, NC-based company will isolate genomic samples and analyze those on both gene-expression and genotyping microarrays. The samples are from a clinical trial IMC is conducting.
The clinical trial is funded through an award received last year from the National Institute on Drug Abuse. The trial uses IMC's TeraGenomics, a data warehousing product to manage, analyze and share Affymetrix GeneChip microarray data to analyze the effectiveness of a compound used to treat methamphetamine addiction.
Financial details were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.